Hydrogels could revolutionize cancer treatment by facilitating targeted drug delivery, reducing adverse effects, and ...

Arcus Biosciences (NYSE:RCUS) said on Thursday that its experimental drug candidate, quemliclustat, has received orphan drug ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

A large-scale bibliometric analysis maps global research on hydrogels as next-generation drug delivery systems for cancer ...

CEL-SCI Corporation (CVM) on Friday announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical ...

A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

A fundamental discovery by University of Missouri scientists could help solve one of the most frustrating challenges in ...

AbbVie has entered into a $700 million licensing agreement with IGI Therapeutics to co-develop ISB 2001, a promising ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...